Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Three-period Crossover, Single Dose Study to Compare the Pharmacokinetics of the Final EC905 Formulation to Marketed Solifenacin (Vesicare®) and Tamsulosin OCAS (Omnic OCAS®)

NCT01953887 is registered in ClinicalTrials.gov with Astellas Pharma Europe B.V. as lead sponsor.

NCT NCT01953887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01953887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Three-period Crossover, Single Dose Study to Compare the Pharmacokinetics of the Final EC905 Formulation to Marketed Solifenacin (Vesicare®) and Tamsulosin OCAS (Omnic OCAS®)
Lead sponsor
Astellas Pharma Europe B.V.
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2010
Completion date
July 31, 2010
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ec905, healthy subjects, pharmacokinetics